Rainmed Medical (HKSE:02297) EPS (Basic): HK$-0.07 (TTM As of Dec. 2025)


HKSE:02297 Rainmed Medical Ltd HKSE:02297
50 GF Score
Price HK$0.24
GF Value HK$0.08
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Rainmed Medical EPS (Basic)?

Rainmed Medical HKSE:02297 +9.09% 50 EPS (Basic) is HK$-0.07 as of Dec. 2025. GuruFocus rates HKSE:02297 with a GF Score™ of 50/100 and a GF Value™ of HK$0.08 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Rainmed Medical's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was HK$-0.03. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.07.

Rainmed Medical's EPS (Diluted) for the six months ended in Dec. 2025 was HK$-0.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.07.

Rainmed Medical's EPS without NRI for the six months ended in Dec. 2025 was HK$-0.04. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.07.

During the past 3 years, the average EPS without NRI Growth Rate was 18.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 10.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Rainmed Medical's highest 3-Year average EPS without NRI Growth Rate was 18.70% per year. The lowest was -3.00% per year. And the median was 12.80% per year.

Rainmed Medical  (HKSE:02297) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Rainmed Medical EPS (Basic) Related Terms

Rainmed Medical EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Rainmed Medical's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rainmed Medical EPS (Basic) Chart

Rainmed Medical Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial -0.67 -1.68 -0.11 -0.11 -0.07

Rainmed Medical Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.07 -0.04 -0.06 -0.03 -0.03
HKSE:02297
50GF Score
Rainmed Medical Ltd HKSE:02297
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rainmed Medical EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Rainmed Medical's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-85.156-0)/1291.938
=-0.07

Rainmed Medical's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-49.618-0)/1403.173
=-0.04

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of HK$-0.07 mean?
Rainmed Medical (HKSE:02297) has a EPS (Basic) of HK$-0.07 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Rainmed Medical and its competitors.
Is Rainmed Medical's EPS (Basic) too high?
Rainmed Medical's current EPS (Basic) is HK$-0.07. Overall, Rainmed Medical has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rainmed Medical's EPS (Basic) compare to ABT and SYK?
Rainmed Medical's EPS (Basic) of HK$-0.07 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Devices & Instruments company?
A good EPS (Basic) depends on the Medical Devices & Instruments industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Rainmed Medical and its competitors. Rainmed Medical's current EPS (Basic) is HK$-0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rainmed Medical stock overvalued right now?
Based on GuruFocus' analysis, Rainmed Medical (HKSE:02297) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.08, compared to a current price of HK$0.24 — trading 200% above its estimated fair value. The current EPS (Basic) is HK$-0.07. Rainmed Medical's overall GF Score™ is 50/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Rainmed Medical (HKSE:02297), the current EPS (Basic) is HK$-0.07 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rainmed Medical (HKSE:02297) Overvalued in 2026?

Based on GuruFocus' analysis, Rainmed Medical stock appears to be overvalued. The current stock price of HK$0.24 is trading 200% above its estimated GF Value™ of HK$0.08. GuruFocus considers Rainmed Medical to be Significantly Overvalued.

Key valuation signals for HKSE:02297:

  • EPS (Basic): HK$-0.07
  • GF Value™: HK$0.08 vs. price of HK$0.24 (200% above fair value)
  • GF Score™: 50/100 with 9 warning signs

No single metric tells the full story. See the HKSE:02297 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rainmed Medical Business Description

Address No. 99, Jinji Lake Avenue, Room NW-05-502, Building 31, Nanopolis Suzhou, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215000
Rainmed Medical Ltd is focused on the design, development, and commercialization of coronary angiography-derived fractional flow reserve systems and coronary angiography-derived index of microcirculatory resistance systems. The company's core products, the caFFR system and the caIMR system, are medical devices used to evaluate the severity of myocardial ischemia arising from coronary artery stenosis and microvascular dysfunction, which are the underlying causes of coronary artery diseases (CAD). It operates in China and Other countries.
50GF Score

Get the complete analysis for HKSE:02297

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.24
Price
HK$0.08
GF Value